Pathogenesis of vascular anomalies

Clinics in Plastic Surgery

Volumn 38, Issue 1, 2011, Pages 7-19

  Boon, Laurence M ^a,b   Ballieux, Fanny ^a   Vikkula, Miikka ^b  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b DE DUVE INSTITUTE   (Belgium)

Author keywords

Angiogenesis; Gene; Genetic; Hemangioma; Mutation; Pathogenesis; Somatic; Vascular malformation

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; ANGIOPOIETIN RECEPTOR; ENDOGLIN; I KAPPA B KINASE GAMMA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NOTCH RECEPTOR; SIMVASTATIN; SMAD4 PROTEIN; TRANSCRIPTION FACTOR FOXC2; TRANSCRIPTION FACTOR SOX18; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

AAGENAES SYNDROME; ANGIOMA SERPIGINOSUM; ARTERIOVENOUS MALFORMATION; CAPILLARY MALFORMATION; CEREBRAL CAVERNOUS MALFORMATION; CONGENITAL BLOOD VESSEL MALFORMATION; CUTANEOMUCOSAL VENOUS MALFORMATION; DRUG MECHANISM; GENE EXPRESSION; GENE LOCUS; GENE MUTATION; GENETIC PREDISPOSITION; GLOMUVENOUS MALFORMATION; HEMANGIOMA; HENNEKAM SYNDROME; HEREDITARY HEMORRHAGIC TELANGIECTASIA JUVENILE POLYPOSIS; HUMAN; HYPOTRICHOSIS LYMPHEDEMA TELANGIECTASIA; LYMPHEDEMA DISTICHIASIS; MEIGE DISEASE; MILROY DISEASE; NONHUMAN; OSTEOPOROSIS LYMPHEDEMA ANHIDROTIC ECTODERMAL DYSPLASIA WITH IMMUNODEFICIENCY; PATHOGENESIS; PATHOPHYSIOLOGY; PENETRANCE; PRIMARY CONGENITAL RESOLVING LYMPHEDEMA; RENDU OSLER WEBER DISEASE; REVIEW; VEIN MALFORMATION;

CAPILLARIES; HEMANGIOMA; HUMANS; LYMPHATIC ABNORMALITIES; LYMPHEDEMA; VASCULAR MALFORMATIONS; VEINS;

EID: 78649289875     PISSN: 00941298     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cps.2010.08.012     Document Type: Review

References (99)

1. Brouillard P., Vikkula M. Vascular malformations: localized defects in vascular morphogenesis. Clin Genet 2003, 63:340.
2. Lohela M., Bry M., Tammela T., et al. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol 2009, 21:154.
3. Brouillard P., Vikkula M. Genetic causes of vascular malformations. Hum Mol Genet 2007, 16(Spec No. 2):R140.
4. Limaye N., Wouters V., Uebelhoer M., et al. Somatic mutations in angiopoietin receptor gene TEK cause solitary and multiple sporadic venous malformations. Nat Genet 2009, 41:118.
5. Holmes L.B. Chorionic villus sampling and hemangiomas. J Craniofac Surg 2009, 1(20 Suppl):675.
6. Pocock B., Boon L.M., Vikkula M. Molecular basis of vascular birthmarks. Sem Plast Surg 2006, 20:149.
7. Jinnin M., Medici D., Park L., et al. Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma. Nat Med 2008, 14:1236.
8. Bischoff J. Progenitor cells in infantile hemangioma. J Craniofac Surg 2009, 20(Suppl 1):695.
9. Boye E., Yu Y., Paranya G., et al. Clonality and altered behavior of endothelial cells from hemangiomas. J Clin Invest 2001, 107:745.
10. Yu Y., Flint A.F., Mulliken J.B., et al. Endothelial progenitor cells in infantile hemangioma. Blood 2004, 103:1373.
11. Yu Y., Fuhr J., Boye E., et al. Mesenchymal stem cells and adipogenesis in hemangioma involution. Stem Cells 2006, 24:1605.
12. Khan Z.A., Melero-Martin J.M., Wu X., et al. Endothelial progenitor cells from infantile hemangioma and umbilical cord blood display unique cellular responses to endostatin. Blood 2006, 108:915.
13. Khan Z.A., Boscolo E., Picard A., et al. Multipotential stem cells recapitulate human infantile hemangioma in immunodeficient mice. J Clin Invest 2008, 118:2592.
14. North P.E., Waner M., Mizeracki A., et al. GLUT1: a newly discovered immunohistochemical marker for juvenile hemangiomas. Hum Pathol 2000, 31:11.
15. Frieden I.J., Reese V., Cohen D. PHACE syndrome. The association of posterior fossa brain malformations, hemangiomas, arterial anomalies, coarctation of the aorta and cardiac defects, and eye abnormalities. Arch Dermatol 1996, 132:307.
16. Limaye N., Boon L.M., Vikkula M. From germline towards somatic mutations in the pathophysiology of vascular anomalies. Hum Mol Genet 2009, 18:R65.
17. Boon L.M., Mulliken J.B., Enjolras O., et al. Glomuvenous malformation (glomangioma) and venous malformation: distinct clinicopathologic and genetic entities. Arch Dermatol 2004, 140:971.
18. Dompmartin A., Acher A., Thibon P., et al. Association of localized intravascular coagulopathy with venous malformations. Arch Dermatol 2008, 144:873.
19. Dompmartin A., Bailleux F., Thibon P., et al. Elevated D-dimer level is diagnostic for venous malformations. Arch Dermatol 2009, 145:1239-1244.
20. Wouters V., Limaye N., Uebelhoer M., et al. Hereditary cutaneomucosal venous malformations are caused by TIE2 mutations with widely variable hyper-phosphorylating effects. Eur J Hum Genet 2010, 18(4):414-420.
21. Boon L.M., Mulliken J.B., Vikkula M., et al. Assignment of a locus for dominantly inherited venous malformations to chromosome 9p. Hum Mol Genet 1994, 3:1583.
22. Vikkula M., Boon L.M., Carraway K.L., et al. Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell 1996, 87:1181.
23. Calvert J.T., Riney T.J., Kontos C.D., et al. Allelic and locus heterogeneity in inherited venous malformations. Hum Mol Genet 1999, 8:1279.
24. Knudson A.G. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 1971, 68:820.
25. Mallory S.B., Enjolras O., Boon L.M., et al. Congenital plaque-type glomuvenous malformations presenting in childhood. Arch Dermatol 2006, 142:892.
26. Goodman T.F., Abele D.C. Multiple glomus tumors. A clinical and electron microscopic study. Arch Dermatol 1971, 103:11.
27. Brouillard P., Enjolras O., Boon L.M., et al. Glomulin and glomuvenous malformation. Inborn errors of development 2008, 1561. Oxford University Press, New York. 2nd edition. C.J. Epstein, R.P. Erickson, A. Wynshaw-Boris (Eds.).
28. Brouillard P., Boon L.M., Mulliken J.B., et al. Mutations in a novel factor, glomulin, are responsible for glomuvenous malformations (" glomangiomas" ). Am J Hum Genet 2002, 70:866.
29. Boon L.M., Brouillard P., Irrthum A., et al. A gene for inherited cutaneous venous anomalies (" glomangiomas" ) localizes to chromosome 1p21-22. Am J Hum Genet 1999, 65:125.
30. Chambraud B., Radanyi C., Camonis J.H., et al. FAP48, a new protein that forms specific complexes with both immunophilins FKBP59 and FKBP12. Prevention by the immunosuppressant drugs FK506 and rapamycin. J Biol Chem 1996, 271:32923.
31. Grisendi S., Chambraud B., Gout I., et al. Ligand-regulated binding of FAP68 to the hepatocyte growth factor receptor. J Biol Chem 2001, 276:46632.
32. Jacobs A.H., Walton R.G. The incidence of birthmarks in the neonate. Pediatrics 1976, 58:218.
33. Mulliken J.B., Young A.E. Vascular birthmarks: hemangiomas and malformations 1988, WB Saunders, Philadelphia.
34. Eerola I., Boon L.M., Watanabe S., et al. Locus for susceptibility for familial capillary malformation ('port-wine stain') maps to 5q. Eur J Hum Genet 2002, 10:375.
35. Eerola I., Boon L.M., Mulliken J.B., et al. Capillary malformation-arteriovenous malformation, a new clinical and genetic disorder caused by RASA1 mutations. Am J Hum Genet 2003, 73:1240.
36. Revencu N., Boon L.M., Mulliken J.B., et al. Parkes Weber syndrome, vein of Galen aneurysmal malformation, and other fast-flow vascular anomalies are caused by RASA1 mutations. Hum Mutat 2008, 29:959.
37. Boon L.M., Mulliken J.B., Vikkula M. RASA1: variable phenotype with capillary and arteriovenous malformations. Curr Opin Genet Dev 2005, 15:265.
38. Thiex R., Mulliken J.B., Revencu N., et al. A novel association between RASA1 mutations and spinal arteriovenous anomalies. Am J Neuroradiol 2010, 31:775-779.
39. Ballester R., Marchuk D., Boguski M., et al. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell 1990, 63:851.
40. Kulkarni S.V., Gish G., van der Geer P., et al. Role of p120 Ras-GAP in directed cell movement. J Cell Biol 2000, 149:457.
41. Govani F.S., Shovlin C.L. Hereditary haemorrhagic telangiectasia: a clinical and scientific review. Eur J Hum Genet 2009, 17:860.
42. McAllister K.A., Grogg K.M., Johnson D.W., et al. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 1994, 8:345.
43. Shovlin C.L., Hughes J.M., Scott J., et al. Characterization of endoglin and identification of novel mutations in hereditary hemorrhagic telangiectasia. Am J Hum Genet 1997, 61:68.
44. Cymerman U., Vera S., Karabegovic A., et al. Characterization of 17 novel endoglin mutations associated with hereditary hemorrhagic telangiectasia. Hum Mutat 2003, 21:482.
45. Johnson D.W., Berg J.N., Gallione C.J., et al. A second locus for hereditary hemorrhagic telangiectasia maps to chromosome 12. Genome Res 1995, 5:21.
46. Johnson D.W., Berg J.N., Baldwin M.A., et al. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet 1996, 13:189.
47. Gallione C.J., Repetto G.M., Legius E., et al. A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). Lancet 2004, 363:852.
48. Cole S.G., Begbie M.E., Wallace G.M., et al. A new locus for hereditary haemorrhagic telangiectasia (HHT3) maps to chromosome 5. J Med Genet 2005, 42:577.
49. Vikkula M. Vascular Pathologies: angiogenomics: towards a genetic nosology and understanding of vascular anomalies. Eur J Hum Genet 2007.
50. Blinkenberg E.O., Brendehaug A., Sandvik A.K., et al. Angioma serpiginosum with oesophageal papillomatosis is an X-linked dominant condition that maps to Xp11.3-Xq12. Eur J Hum Genet 2007, 15:543.
51. Katta R., Wagner A. Angioma serpiginosum with extensive cutaneous involvement. J Am Acad Dermatol 2000, 42:384.
52. Houge G., Oeffner F., Grzeschik K.H. An Xp11.23 deletion containing PORCN may also cause angioma serpiginosum, a cosmetic skin disease associated with extreme skewing of X-inactivation. Eur J Hum Genet 2008, 16:1027.
53. Grzeschik K.H., Bornholdt D., Oeffner F., et al. Deficiency of PORCN, a regulator of Wnt signaling, is associated with focal dermal hypoplasia. Nat Genet 2007, 39:833.
54. Rigamonti D., Hadley M.N., Drayer B.P., et al. Cerebral cavernous malformations. Incidence and familial occurrence. N Engl J Med 1988, 319:343.
55. Revencu N., Vikkula M. Cerebral cavernous malformation: new molecular and clinical insights. J Med Genet 2006, 43:716.
56. Laberge-le Couteulx S., Jung H.H., Labauge P., et al. Truncating mutations in CCM1, encoding KRIT1, cause hereditary cavernous angiomas. Nat Genet 1999, 23:189.
57. Sahoo T., Johnson E.W., Thomas J.W., et al. Mutations in the gene encoding KRIT1, a Krev-1/rap1a binding protein, cause cerebral cavernous malformations (CCM1). Hum Mol Genet 1999, 8:2325.
58. Serebriiskii I., Estojak J., Sonoda G., et al. Association of Krev-1/rap1a with Krit1, a novel ankyrin repeat-containing protein encoded by a gene mapping to 7q21-22. Oncogene 1997, 15:1043.
59. Denier C., Goutagny S., Labauge P., et al. Mutations within the MGC4607 gene cause cerebral cavernous malformations. Am J Hum Genet 2004, 74:326.
60. Liquori C.L., Berg M.J., Siegel A.M., et al. Mutations in a gene encoding a novel protein containing a phosphotyrosine-binding domain cause type 2 cerebral cavernous malformations. Am J Hum Genet 2003, 73:1459.
61. Bergametti F., Denier C., Labauge P., et al. Mutations within the programmed cell death 10 gene cause cerebral cavernous malformations. Am J Hum Genet 2005, 76:42.
62. Liquori C.L., Berg M.J., Squitieri F., et al. Low frequency of PDCD10 mutations in a panel of CCM3 probands: potential for a fourth CCM locus. Hum Mutat 2006, 27:118.
63. Riant F., Bergametti F., Ayrignac X., et al. Recent insights into cerebral cavernous malformations: the molecular genetics of CCM. Febs J. 2010, 277(5):1070-1075.
64. Labauge P., Enjolras O., Bonerandi J.J., et al. An association between autosomal dominant cerebral cavernomas and a distinctive hyperkeratotic cutaneous vascular malformation in 4 families. Ann Neurol 1999, 45:250.
65. Eerola I., Plate K.H., Spiegel R., et al. KRIT1 is mutated in hyperkeratotic cutaneous capillary-venous malformation associated with cerebral capillary malformation. Hum Mol Genet 2000, 9:1351.
66. Toll A., Parera E., Gimenez-Arnau A.M., et al. Cutaneous venous malformations in familial cerebral cavernomatosis caused by KRIT1 gene mutations. Dermatology 2009, 218:307.
67. Sirvente J., Enjolras O., Wassef M., et al. Frequency and phenotypes of cutaneous vascular malformations in a consecutive series of 417 patients with familial cerebral cavernous malformations. J Eur Acad Dermatol Venereol 2009, 23:1066.
68. Gault J., Shenkar R., Recksiek P., et al. Biallelic somatic and germ line CCM1 truncating mutations in a cerebral cavernous malformation lesion. Stroke 2005, 36:872.
69. Akers A.L., Johnson E., Steinberg G.K., et al. Biallelic somatic and germline mutations in cerebral cavernous malformations (CCMs): evidence for a two-hit mechanism of CCM pathogenesis. Hum Mol Genet 2009, 18:919.
70. Pagenstecher A., Stahl S., Sure U., et al. A two-hit mechanism causes cerebral cavernous malformations: complete inactivation of CCM1, CCM2 or CCM3 in affected endothelial cells. Hum Mol Genet 2009, 18:911.
71. Denier C., Gasc J.M., Chapon F., et al. Krit1/cerebral cavernous malformation 1 mRNA is preferentially expressed in neurons and epithelial cells in embryo and adult. Mech Dev 2002, 117:363.
72. Zawistowski J.S., Stalheim L., Uhlik M.T., et al. CCM1 and CCM2 protein interactions in cell signaling: implications for cerebral cavernous malformations pathogenesis. Hum Mol Genet 2005, 14:2521.
73. Boulday G., Blecon A., Petit N., et al. Tissue-specific conditional CCM2 knockout mice establish the essential role of endothelial CCM2 in angiogenesis: implications for human cerebral cavernous malformations. Dis Model Mech 2009, 2:168.
74. Plummer N.W., Gallione C.J., Srinivasan S., et al. Loss of p53 sensitizes mice with a mutation in Ccm1 (KRIT1) to development of cerebral vascular malformations. Am J Pathol 2004, 165:1509.
75. Uhlik M.T., Abell A.N., Johnson N.L., et al. Rac-MEKK3-MKK3 scaffolding for p38 MAPK activation during hyperosmotic shock. Nat Cell Biol 2003, 5:1104.
76. Hilder T.L., Malone M.H., Bencharit S., et al. Proteomic identification of the cerebral cavernous malformation signaling complex. J Proteome Res 2007, 6:4343.
77. Whitehead K.J., Plummer N.W., Adams J.A., et al. Ccm1 is required for arterial morphogenesis: implications for the etiology of human cavernous malformations. Development 2004, 131:1437.
78. Whitehead K.J., Chan A.C., Navankasattusas S., et al. The cerebral cavernous malformation signaling pathway promotes vascular integrity via Rho GTPases. Nat Med 2009, 15:177.
79. Lazareth I. Classification of lymphedema. Rev Med Interne 2002, 23(Suppl 3):375s.
80. Irrthum A., Karkkainen M.J., Devriendt K., et al. Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase. Am J Hum Genet 2000, 67:295.
81. Finegold D.N., Kimak M.A., Lawrence E.C., et al. Truncating mutations in FOXC2 cause multiple lymphedema syndromes. Hum Mol Genet 2001, 10:1185.
82. Doffinger R., Smahi A., Bessia C., et al. X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-kappaB signaling. Nat Genet 2001, 27:277.
83. Irrthum A., Devriendt K., Chitayat D., et al. Mutations in the transcription factor gene SOX18 underlie recessive and dominant forms of hypotrichosis-lymphedema-telangiectasia. Am J Hum Genet 2003, 72:1470.
84. Alders M., Hogan B.M., Gjini E., et al. Mutations in CCBE1 cause generalized lymph vessel dysplasia in humans. Nat Genet 2009.
85. Brice G., Child A.H., Evans A., et al. Milroy disease and the VEGFR-3 mutation phenotype. J Med Genet 2005, 42:98.
86. Ghalamkarpour A., Morlot S., Raas-Rothschild A., et al. Hereditary lymphedema type I associated with VEGFR3 mutation: the first de novo case and atypical presentations. Clin Genet 2006, 70:330.
87. Ghalamkarpour A., Debauche C., Haan E., et al. Sporadic in utero generalized edema caused by mutations in the lymphangiogenic genes VEGFR3 and FOXC2. J Pediatr 2009, 155:90.
88. Ghalamkarpour A., Holnthoner W., Saharinen P., et al. Recessive primary congenital lymphoedema caused by a VEGFR3 mutation. J Med Genet 2009, 46:399.
89. Dale R.F. The inheritance of primary lymphoedema. J Med Genet 1985, 22:274.
90. Xue Y., Cao R., Nilsson D., et al. FOXC2 controls Ang-2 expression and modulates angiogenesis, vascular patterning, remodeling, and functions in adipose tissue. Proc Natl Acad Sci U S A 2008, 105:10167.
91. Hayashi H., Sano H., Seo S., et al. The Foxc2 transcription factor regulates angiogenesis via induction of integrin beta3 expression. J Biol Chem 2008, 283:23791.
92. Hayashi H., Kume T. Foxc transcription factors directly regulate Dll4 and Hey2 expression by interacting with the VEGF-Notch signaling pathways in endothelial cells. PLoS One 2008, 3:e2401.
93. Petrova T.V., Karpanen T., Norrmen C., et al. Defective valves and abnormal mural cell recruitment underlie lymphatic vascular failure in lymphedema distichiasis. Nat Med 2004, 10:974.
94. Hennekam R.C., Geerdink R.A., Hamel B.C., et al. Autosomal recessive intestinal lymphangiectasia and lymphedema, with facial anomalies and mental retardation. Am J Med Genet 1989, 34:593.
95. Hogan B.M., Bos F.L., Bussmann J., et al. Ccbe1 is required for embryonic lymphangiogenesis and venous sprouting. Nat Genet 2009, 41:396.
96. Connell F, Kalidas K, Ostergaard P, et al. Linkage and sequence analysis indicate that CCBE1 is mutated in recessively inherited generalised lymphatic dysplasia. Hum Genet 127:231.
97. Malik S., Grzeschik K.H. Congenital, low penetrance lymphedema of lower limbs maps to chromosome 6q16.2-q22.1 in an inbred Pakistani family. Hum Genet 2008, 123:197.
98. Sigstad H., Aagenaes O., Bjorn-Hansen R.W., et al. Primary lymphoedema combined with hereditary recurrent intrahepatic cholestasis. Acta Med Scand 1970, 188:213.
99. Bull L.N., Roche E., Song E.J., et al. Mapping of the locus for cholestasis-lymphedema syndrome (Aagenaes syndrome) to a 6.6-cM interval on chromosome 15q. Am J Hum Genet 2000, 67:994.